{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:32Z","timestamp":1789469132392,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100016003","name":"Istanbul University Cerrahpa\u015fa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100016003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The lifespan of patients with chronic phase chronic myeloid leukemia undergoing tyrosine kinase inhibitor treatment has nearly reached that of the general population. However, treatment switching due to resistance or intolerance demonstrates the significance of effective communication between patients and physicians in decision-making. This study aimed to evaluate priorities, expectations, and perceptions of managing CML-CP from the perspective of both patients and physicians in T\u00fcrkiye. This cross-sectional survey study was conducted from July to December 2024 by the Turkish Society of Hematology. A total of 129 hematologists completed a web-based survey, while 120 patients receiving TKI treatment completed a structured telephone survey. Eleven common questions were analyzed descriptively to compare perspectives. Patients (53% male; median age 54 years) and physicians agreed on essential information to be communicated at treatment start, although priorities differed. Patients prioritized information about disease progression, daily life impact, and treatment effectiveness, whereas physicians focused on treatment safety, patient monitoring, and follow-up assessments. Patients (40.8%) emphasized treatment effectiveness when switching therapies, while physicians (46.7%) focused on the manageability of adverse events. Approximately 25% of patients reported suboptimal adherence, mostly due to forgetfulness (52%). Follow-up visits occurred every 2 to 3 months, with a mean duration of approximately 10 min. Although patients and physicians shared broadly similar views, discrepancies existed in their prioritization of factors and overall opinions. Patients expressed greater optimism regarding the disease impact on their daily lives. Enhancing communication between patients and physicians, as well as promoting shared decision-making during treatment transitions, may improve adherence and disease management outcomes.<\/jats:p>","DOI":"10.1007\/s00277-026-07103-z","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:04:58Z","timestamp":1781615098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A survey on the management of chronic myeloid leukemia in chronic phase from the perspectives of both patients and physicians"],"prefix":"10.1007","volume":"105","author":[{"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samet","family":"Yaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkerim","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"\u00d6zmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"G\u00fcrkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dcnal","family":"Ata\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevin Alayvaz","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"Mehtap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Say\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe","family":"Uysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Fatih","family":"Orhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130brahim Ethem","family":"P\u0131nar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Soyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Baysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"G\u00fcr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bar\u0131\u015f","family":"U\u00e7ar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"7103_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajh.24249","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E (2016) Chronic myeloid leukemia: First-line drug of choice. Am J Hematol 91:59\u201366. https:\/\/doi.org\/10.1002\/ajh.24249","journal-title":"Am J Hematol"},{"key":"7103_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/ejh.13524","volume":"106","author":"C Gambacorti-Passerini","year":"2021","unstructured":"Gambacorti-Passerini C, Chen C, Davis C, Sen GP, Guyan C, Hehlmann R et al (2021) Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic\u2010phase CML in clinical practice: 3\u2010year European SIMPLICITY data. Eur J Haematol 106:82\u201389. https:\/\/doi.org\/10.1111\/ejh.13524","journal-title":"Eur J Haematol"},{"key":"7103_CR3","doi-asserted-by":"publisher","first-page":"IJH40","DOI":"10.2217\/ijh-2021-0008","volume":"11","author":"G Saydam","year":"2022","unstructured":"Saydam G, Unal A, Haznedaroglu IC, Hacihanifioglu A, Mehtap O, Kurtoglu E et al (2022) Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia. Int J Hematol Oncol 11:IJH40. https:\/\/doi.org\/10.2217\/ijh-2021-0008","journal-title":"Int J Hematol Oncol"},{"key":"7103_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/17474086.2022.2044779","volume":"15","author":"AE E\u015fkazan","year":"2022","unstructured":"E\u015fkazan AE, Ali R, Aln\u0131geni\u015f E, Ayy\u0131ld\u0131z O, Haznedaro\u011flu \u0130, K\u0131rk\u0131zlar O et al (2022) Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting. Expert Rev Hematol Taylor Francis 15:97\u2013106. https:\/\/doi.org\/10.1080\/17474086.2022.2044779","journal-title":"Expert Rev Hematol Taylor Francis"},{"key":"7103_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-025-01242-8","volume":"15","author":"L Busque","year":"2025","unstructured":"Busque L, Beaudet M-\u00c9, Harnois M, Moussa H, Szuber N, Mollica L et al (2025) Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study. Blood Cancer J Nat Publishing Group 15:35. https:\/\/doi.org\/10.1038\/s41408-025-01242-8","journal-title":"Blood Cancer J Nat Publishing Group"},{"key":"7103_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3324\/haematol.2025.287772","volume":"111","author":"F Lang","year":"2025","unstructured":"Lang F, Pemberton-Whiteley Z, Clements J, Ruiz C, Rea D, Machado L et al (2025) Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey. Haematologica 111:597\u2013608. https:\/\/doi.org\/10.3324\/haematol.2025.287772","journal-title":"Haematologica"},{"key":"7103_CR7","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leuk Nat Publishing Group 34:966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leuk Nat Publishing Group"},{"key":"7103_CR8","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H et al (2025) 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leuk Nat Publishing Group 39:1797\u20131813. https:\/\/doi.org\/10.1038\/s41375-025-02664-w","journal-title":"Leuk Nat Publishing Group"},{"key":"7103_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41375-025-02826-w","volume":"40","author":"P Ernst","year":"2026","unstructured":"Ernst P, Lohse C, Lauseker M, Gei\u00dfler J, le Coutre P, Br\u00fcmmendorf TH et al (2026) Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective. Leukemia 40:29\u201336. https:\/\/doi.org\/10.1038\/s41375-025-02826-w","journal-title":"Leukemia"},{"key":"7103_CR10","doi-asserted-by":"publisher","first-page":"204062072514092","DOI":"10.1177\/20406207251409297","volume":"17","author":"JJ Han","year":"2026","unstructured":"Han JJ, Constantinescu C, Kim Y, Kim H (2026) Understanding disease management and the patient journey in chronic myeloid leukemia: results from the CML SUN survey in South Korean patients and physicians. Ther Adv Hematol 17:20406207251409297. https:\/\/doi.org\/10.1177\/20406207251409297","journal-title":"Ther Adv Hematol"},{"key":"7103_CR11","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1016\/S2352-3026(18)30051-6","volume":"5","author":"G Thanarajasingam","year":"2018","unstructured":"Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC et al (2018) Beyond Maximum Grade: Modernizing Adverse Event Assessment and Reporting in Haematologic Malignancies. Lancet Haematol 5:e563\u2013e598. https:\/\/doi.org\/10.1016\/S2352-3026(18)30051-6","journal-title":"Lancet Haematol"},{"key":"7103_CR12","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/jnci\/djab017","volume":"113","author":"E Basch","year":"2021","unstructured":"Basch E, Yap C (2021) Patient-reported outcomes for tolerability assessment in phase I cancer clinical trials. J Natl Cancer Inst 113:943\u2013944. https:\/\/doi.org\/10.1093\/jnci\/djab017","journal-title":"J Natl Cancer Inst"},{"key":"7103_CR13","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde M-A, De Bock R, Verhoef G, Zach\u00e9e P, Berneman Z et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:5401\u20135411. https:\/\/doi.org\/10.1182\/blood-2008-12-196543","journal-title":"Blood"},{"key":"7103_CR14","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon F-X, Eliasson L, Milojkovic D, Bua M et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381\u20132388. https:\/\/doi.org\/10.1200\/JCO.2009.26.3087","journal-title":"J Clin Oncol"},{"key":"7103_CR15","doi-asserted-by":"publisher","first-page":"e112705","DOI":"10.1136\/bmjopen-2025-112705","volume":"16","author":"S Mingels","year":"2026","unstructured":"Mingels S, Cloots MJJ, Smit Y, Blijlevens NMA, Posthuma EFM, Dekker ALAJ et al (2026) Decisional needs among patients and physicians in the treatment of chronic myeloid leukaemia: a qualitative analysis in the Netherlands. BMJ Open 16:e112705. https:\/\/doi.org\/10.1136\/bmjopen-2025-112705","journal-title":"BMJ Open"},{"key":"7103_CR16","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1182\/blood-2021-147739","volume":"138","author":"Z Pemberton-Whiteley","year":"2021","unstructured":"Pemberton-Whiteley Z, Cortes JE, Clements J, Ruiz C, Rea D, Machado L et al (2021) Patient and physician perspectives of unmet needs in cml - designing the CML SUN survey. Blood 138:4986. https:\/\/doi.org\/10.1182\/blood-2021-147739","journal-title":"Blood"},{"key":"7103_CR17","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3324\/haematol.2013.093724","volume":"99","author":"F Efficace","year":"2014","unstructured":"Efficace F, Rosti G, Aaronson N, Cottone F, Angelucci E, Molica S et al (2014) Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica 99:788\u2013793. https:\/\/doi.org\/10.3324\/haematol.2013.093724","journal-title":"Haematologica"},{"key":"7103_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1477-7525-11-167","volume":"11","author":"I Hirji","year":"2013","unstructured":"Hirji I, Gupta S, Goren A, Chirovsky DR, Moadel AB, Olavarria E et al (2013) Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient\u2019s perspective. Health Qual Life Outcomes 11:167. https:\/\/doi.org\/10.1186\/1477-7525-11-167","journal-title":"Health Qual Life Outcomes"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07103-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07103-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07103-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:56Z","timestamp":1789465376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07103-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7103"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07103-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.E.E. has received advisory board honoraria, speaker bureau honoraria, and travel grants from Novartis, Bristol Myers Squibb, and Pfizer outside the present study. He has also received advisory board honoraria from Ascentage Pharma outside the present study. O.G. and B.U. are employees of Novartis. All other authors report no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"395"}}